NO20090910L - Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister - Google Patents

Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister

Info

Publication number
NO20090910L
NO20090910L NO20090910A NO20090910A NO20090910L NO 20090910 L NO20090910 L NO 20090910L NO 20090910 A NO20090910 A NO 20090910A NO 20090910 A NO20090910 A NO 20090910A NO 20090910 L NO20090910 L NO 20090910L
Authority
NO
Norway
Prior art keywords
adrenergic agonists
sulfonamide derivatives
muscarinic antagonists
disorders
compounds
Prior art date
Application number
NO20090910A
Other languages
English (en)
Norwegian (no)
Inventor
Graham Lunn
David Anthony Price
Lyn Howard Jones
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of NO20090910L publication Critical patent/NO20090910L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20090910A 2006-10-04 2009-02-26 Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister NO20090910L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82809906P 2006-10-04 2006-10-04
PCT/IB2007/002896 WO2008041095A1 (fr) 2006-10-04 2007-09-21 Dérivés de sulfonamide en tant qu'agonistes adrénergiques et qu'antagonistes muscariniques

Publications (1)

Publication Number Publication Date
NO20090910L true NO20090910L (no) 2009-03-24

Family

ID=38947725

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090910A NO20090910L (no) 2006-10-04 2009-02-26 Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister

Country Status (25)

Country Link
US (1) US20080090873A1 (fr)
EP (1) EP2074094A1 (fr)
JP (1) JP2010505810A (fr)
KR (1) KR20090050104A (fr)
CN (1) CN101522622A (fr)
AP (1) AP2009004791A0 (fr)
AR (1) AR063118A1 (fr)
AU (1) AU2007303909A1 (fr)
BR (1) BRPI0719270A2 (fr)
CA (1) CA2665385A1 (fr)
CL (1) CL2007002791A1 (fr)
CO (1) CO6180437A2 (fr)
CR (1) CR10700A (fr)
EA (1) EA200900337A1 (fr)
IL (1) IL197244A0 (fr)
MA (1) MA30778B1 (fr)
MX (1) MX2009002209A (fr)
NO (1) NO20090910L (fr)
PE (1) PE20080831A1 (fr)
RS (1) RS20090137A (fr)
TN (1) TN2009000112A1 (fr)
TW (1) TW200823185A (fr)
UY (1) UY30617A1 (fr)
WO (1) WO2008041095A1 (fr)
ZA (1) ZA200901320B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドPfizer Limited 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
WO2011061527A1 (fr) 2009-11-17 2011-05-26 Astrazeneca Ab Combinaisons qui comprennent un modulateur du récepteur glucocorticoïde, destinées au traitement de maladies respiratoires
WO2011081937A1 (fr) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Composés de type corticostéroïde-bêta-agoniste-antagoniste muscarinique pour applications thérapeutiques
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (fr) 2010-05-13 2011-11-16 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2592078A1 (fr) 2011-11-11 2013-05-15 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
MA38260B1 (fr) 2012-12-18 2018-04-30 Almirall Sa Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
CN106336406B (zh) * 2015-07-10 2020-01-03 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的八氢并环戊二烯衍生物及其在医药上的用途
US11447485B2 (en) 2016-12-14 2022-09-20 Beijing Showby Pharmaceutical Co., Ltd. Class of bifunctional compounds with quanternary ammonium salt structure
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (fr) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Inhibiteurs de la kinase p38 réduisant l'expression du gène dux4 et des gènes aval pour le traitement de la fshd
WO2019110521A1 (fr) * 2017-12-04 2019-06-13 Friedrich-Alexander-Universität Erlangen-Nürnberg Ligands des récepteurs muscariniques à substitution fluorophényle ayant une sélectivité pour m3 sur m2
CN116033893A (zh) 2020-06-26 2023-04-28 迈兰制药英国有限公司 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7317102B2 (en) * 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
US7358244B2 (en) * 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
ATE369333T1 (de) * 2004-01-22 2007-08-15 Pfizer Sulfonamidderivate zur behandlung von krankheiten
US7320990B2 (en) * 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound

Also Published As

Publication number Publication date
MA30778B1 (fr) 2009-10-01
EA200900337A1 (ru) 2009-10-30
CO6180437A2 (es) 2010-07-19
WO2008041095A1 (fr) 2008-04-10
TW200823185A (en) 2008-06-01
ZA200901320B (en) 2010-04-28
PE20080831A1 (es) 2008-06-20
MX2009002209A (es) 2009-03-16
BRPI0719270A2 (pt) 2014-03-11
EP2074094A1 (fr) 2009-07-01
KR20090050104A (ko) 2009-05-19
US20080090873A1 (en) 2008-04-17
AR063118A1 (es) 2008-12-30
AP2009004791A0 (en) 2009-04-30
JP2010505810A (ja) 2010-02-25
CN101522622A (zh) 2009-09-02
RS20090137A (en) 2010-06-30
CA2665385A1 (fr) 2008-04-10
IL197244A0 (en) 2009-12-24
UY30617A1 (es) 2008-05-31
AU2007303909A1 (en) 2008-04-10
CR10700A (es) 2009-04-24
TN2009000112A1 (fr) 2010-08-19
CL2007002791A1 (es) 2008-04-11

Similar Documents

Publication Publication Date Title
NO20090910L (no) Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister
NO20084005L (no) Aminderivater
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
NO20062983L (no) Sulfonamid-derivater for behandling av sykdommer
MY139690A (en) Sulfonamide derivatives for the treatment of diseases.
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
ATE537170T1 (de) Cgrp-rezeptorantagonisten
MXPA05012840A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
GEP20125437B (en) New sulfonamide derivatives as bradykinin antagonists
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
EA200601462A1 (ru) Соединения для лечения заболеваний
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
NO20076515L (no) Hydantoinforbindelser
WO2007073303A3 (fr) Nouveaux composes iii
HK1116477A1 (en) Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders
WO2006078554A3 (fr) Antagonistes de recepteurs du peptide lie au gene de la calcitonine (cgrp)
WO2008074803A3 (fr) Composés
NO20080033L (no) Kinolinderivater som NK3-antagonister
EA200601510A1 (ru) Производные фенилэтаноламина в качестве бета-2-агонистов
ATE440836T1 (de) Verbindungen
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
NO20081587L (no) Aerosolformulering for inhalering
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application